MedTrace Logo

A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

NCT02623127 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-01-23

No results posted yet for this study

Summary

This study aims to investigate the clinical activity of sunitinib in patients with advanced thymic carcinoma who have failed chemotherapy.

Conditions

  • Thymic Carcinoma

Interventions

DRUG

Sunitinib

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jong Seok Lee, MD, PhD · Seoul National University Bundang Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-31
Completion
2018-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623127 on ClinicalTrials.gov